Tibet AIM Pharm. Inc. (SHE:002826)

Market Cap	3.65B +86.0%
Revenue (ttm)	670.32M +4.7%
Net Income	93.44M +153.7%
EPS	0.51 +155.6%
Shares Out	187.27M
PE Ratio	38.16
Forward PE	n/a
Dividend	0.10 (0.51%)
Ex-Dividend Date	Jun 24, 2025

Volume	7,078,753
Average Volume	4,946,353
Open	20.51
Previous Close	19.52
Day's Range	19.16 - 20.51
52-Week Range	10.40 - 26.83
Beta	0.53
RSI	39.23
Earnings Date	Apr 28, 2026

About Tibet AIM Pharm.

Tibet AIM Pharm. Inc. engages in the research and development, manufacturing, and sale of medical products in China. The company’s products include Miglitol tablets for diabetes; ethnic medicine products, suitable for treating breast lobular hyperplasia, uterine fibroids, and ovarian cysts; gynecology and obstetrics; and NalMefene hydrochloride injection for various acute poisoning, such as alcohol, organic phosphor, CO, sedative-hypnotic, opioid substance, severe infection, shock, cord injury, and brain, as well as coma, spinal cord injury, ce...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2003
• Employees: 403
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002826

Financial Performance

In 2025, Tibet AIM Pharm.'s revenue was 636.27 million, a decrease of -2.39% compared to the previous year's 651.88 million. Earnings were 92.58 million, an increase of 101.57%.